Dediabetes Logo
Evidence Hub
Learn what works
Evidence Explorer
Search the complete evidence graph
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Ticagrelor monotherapy reduces bleeding in diabetic ACS patients

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated July 6, 2026

Key finding

There was no significant difference in the incidence of MACE between the two groups during 12 months of follow-up.

This study evaluated ticagrelor monotherapy after 3 months of dual antiplatelet therapy in diabetic patients with acute coronary syndrome, finding no significant difference in major adverse cardiovascular events.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated ticagrelor monotherapy after 3 months of dual antiplatelet therapy in diabetic patients with acute coronary syndrome, finding no significant difference in major adverse cardiovascular events.

Clinical relevance

These findings are significant for clinicians managing diabetic patients with acute coronary syndrome, as they suggest that switching to ticagrelor monotherapy may reduce bleeding risks without compromising cardiovascular safety. This could lead to more tailored treatment strategies that balance efficacy and safety.

Keep in mind

The study's sample size and population may limit generalizability. The follow-up period was only 12 months, which may not capture long-term outcomes. Effect sizes were unclear, limiting the strength of conclusions.

Published in

Journal Reference

Publication details and source links for this paper.

Nour EMSI, Mohamed TMZ, Khaled AFAM, Khaled AF, Mina MAI. Ticagrelor Monotherapy After 3 Months of Dual Antiplatelet Treatment in Diabetic Patients with Acute Coronary Syndrome. BMC Cardiovascular Disorders. 2026;26:300. doi:10.1186/s12872-026-05708-w

View DOIView on PubMedView on PMC

Main Effects

No significant difference in major adverse cardiovascular events between ticagrelor monotherapy and dual therapy (p-value: null).

Ticagrelor monotherapy was associated with a decrease in overall bleeding events, particularly mild bleeding.

Rates of moderate or severe bleeding were comparable between both treatment groups.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Aspirin, Ticagrelor monotherapy after 3 months of DAPT and Bleeding events, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

This study contributes evidence to

Intervention

Aspirin

Outcome

Bleeding events

Evidence topic

Cardiovascular Risk

Primary intervention

Aspirin

Primary outcomes

  • Bleeding events
  • Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topics

Cardiovascular Risk

Primary intervention

Aspirin

Primary outcomes

Bleeding eventsComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 63

1

Related topics

4

Evidence pairs

45

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 4 evidence relationships
  • Includes primary outcome data
  • Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence topic

Cardiovascular Risk

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

Bleeding events

Aspirin → Bleeding events

Aspirin → Bleeding events

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Bleeding events

Ticagrelor monotherapy after 3 months of DAPT → Bleeding events

Ticagrelor monotherapy after 3 months of DAPT → Bleeding events

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Ticagrelor monotherapy after 3 months of DAPT → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Ticagrelor monotherapy after 3 months of DAPT → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • No change in major adverse cardiovascular events with ticagrelor monotherapy.
  • Ticagrelor monotherapy showed a decrease in overall bleeding events.
  • Moderate or severe bleeding rates were similar in both treatment groups.
who this applies

Who this applies to

  • Diabetic patients diagnosed with acute coronary syndrome.
  • Patients who have completed at least three months of dual antiplatelet therapy.
keep in mind

Keep in Mind

  • Results may not apply to non-diabetic patients or those with different coronary conditions.
  • The study did not assess long-term outcomes beyond 12 months.
  • Further research is needed to confirm findings in larger, diverse populations.
between the lines

Between the Lines

  • The study's sample size and population may limit generalizability.
  • The follow-up period was only 12 months, which may not capture long-term outcomes.
  • Effect sizes were unclear, limiting the strength of conclusions.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on Aspirin and Bleeding events, Aspirin and Cardiovascular Outcomes.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Ticagrelor monotherapy after 3 months of DAPT improve bleeding events?

Emerging Evidence

Ticagrelor monotherapy after 3 months of DAPT appears to improve Bleeding events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Bleeding events

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence

Does Aspirin improve bleeding events?

Emerging Evidence

Current evidence does not show a clear benefit of Aspirin for Bleeding events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Bleeding events

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence

Does Aspirin improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?

Emerging Evidence

Current evidence does not show a clear benefit of Aspirin for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence

Does Ticagrelor monotherapy after 3 months of DAPT improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?

Emerging Evidence

Current evidence does not show a clear benefit of Ticagrelor monotherapy after 3 months of DAPT for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Aug 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Aspirin and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Ticagrelor monotherapy after 3 months of DAPT and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Aspirin and Bleeding eventsAll studies on Ticagrelor monotherapy after 3 months of DAPT and Bleeding events

Related research

Read related research summaries.

HbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsIntensive glycemic control may lower cardiovascular events in some diabetes patientsLinking Eye Screening Data Improves Understanding of Diabetes TreatmentsTighter glycaemic targets may reduce serious infant morbidityWomen and frailty linked to poorer adherence in diabetes trial

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.